New Oral Insulin Solution May Replace Painful Daily Injections for Diabetics
Jerusalem-based Oramed Pharmaceuticals is planning to revolutionize the treatment of diabetes by offering an oral-based insulin solution to replace daily injections. The current practice is for those who suffer from diabetes to inject insulin directly into their bloodstream in order to control their blood sugar levels, but this treatment has several known downsides, such as the discomfort of an injection, weight gain, and inefficiencies due to not being delivered directly to the liver. Oramed’s oral insulin pill (ORMD-0801), based on its patented POD™ (Protein Oral Delivery) technology, has been proven to deliver better glucose control and to reduce hyper- and hypoglycemia as well as the occurrence of unwanted weight gain. ORMD-0801 performed well and demonstrated no serious adverse side effects in initial clinical trials, and is now undergoing advanced clinical trials by the U.S. FDA to assess its safety and efficacy in treating both type 1 and type 2 diabetes.